162 related articles for article (PubMed ID: 28466283)
1. Advanced Hodgkin's lymphoma: End-of-treatment FDG-PET should be maintained.
Hindié E; Mesguich C; Bouabdallah K; Milpied N
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1254-1257. PubMed ID: 28466283
[No Abstract] [Full Text] [Related]
2. The use of positron emission tomography with [18F] 2-fluoro-D-2-deoxyglucose (FDG-PET) in Hodgkin and non-Hodgkin's lymphoma.
Chiusolo P; Sica S; Leone G
Hematology; 2003 Dec; 8(6):403-8. PubMed ID: 14668036
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG PET as a routine test for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: where is the evidence?
Juweid ME
J Nucl Med; 2008 Jan; 49(1):9-12. PubMed ID: 18077522
[No Abstract] [Full Text] [Related]
4. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
[TBL] [Abstract][Full Text] [Related]
5. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease.
Even-Sapir E; Lievshitz G; Perry C; Herishanu Y; Lerman H; Metser U
Radiol Clin North Am; 2007 Jul; 45(4):697-709, vii. PubMed ID: 17706534
[TBL] [Abstract][Full Text] [Related]
6. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
Qiu L; Chen Y; Wu J
Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
[TBL] [Abstract][Full Text] [Related]
7. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas.
Kumar R; Maillard I; Schuster SJ; Alavi A
Radiol Clin North Am; 2004 Nov; 42(6):1083-100. PubMed ID: 15488559
[TBL] [Abstract][Full Text] [Related]
8. Hodgkin's and non-Hodgkin's lymphomas.
Rademaker J
Radiol Clin North Am; 2007 Jan; 45(1):69-83. PubMed ID: 17157624
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease.
Spaepen K; Mortelmans L
Q J Nucl Med; 2001 Sep; 45(3):269-73. PubMed ID: 11788819
[TBL] [Abstract][Full Text] [Related]
10. Stage IE non-Hodgkin's thyroid lymphoma on (18)F-FDG-PET/CT.
Mehta A; Muthukrishnan A
Hell J Nucl Med; 2011; 14(2):186-7. PubMed ID: 21761029
[No Abstract] [Full Text] [Related]
11. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
Shen YY; Kao A; Yen RF
Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
[TBL] [Abstract][Full Text] [Related]
12. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
13. Giant cardiac tumour thrombus on staging contrast enhanced ¹⁸F-FDG PET/CT in a case of non-Hodgkin's lymphoma.
Jeph S; Thakur K; Shamim SA; Verma K; Aggarwal B; Aggarwal A
Rev Esp Med Nucl Imagen Mol; 2014; 33(5):328-9. PubMed ID: 24618093
[No Abstract] [Full Text] [Related]
14. [Malignant lymphoma].
Okamoto R
Gan To Kagaku Ryoho; 2009 Dec; 36(13):2532-6. PubMed ID: 20009452
[TBL] [Abstract][Full Text] [Related]
15. Predicting outcomes after a positive interim FDG-PET scan in advanced Hodgkin's lymphoma.
Crump M
Lancet Oncol; 2017 Apr; 18(4):416-418. PubMed ID: 28237632
[No Abstract] [Full Text] [Related]
16. Pitfalls of positron emission tomography for assessing relapse in Hodgkin's disease: a case report.
Pitini V; Navarra G; Cavallari V; Arrigo C; Naro C; Altavilla G
Haematologica; 2006 Aug; 91(8 Suppl):ECR38. PubMed ID: 16923522
[TBL] [Abstract][Full Text] [Related]
17. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma.
Delbeke D; Stroobants S; de Kerviler E; Gisselbrecht C; Meignan M; Conti PS
Oncologist; 2009; 14 Suppl 2():30-40. PubMed ID: 19819922
[TBL] [Abstract][Full Text] [Related]
18. Diffuse skeletal muscle F-18 fluorodeoxyglucose uptake in advanced primary muscle non-Hodgkin's lymphoma.
Broski SM; Bou-Assaly W; Gross MD; Fig LM
Clin Nucl Med; 2009 Apr; 34(4):251-3. PubMed ID: 19300063
[TBL] [Abstract][Full Text] [Related]
19. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
Specht L
Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
[TBL] [Abstract][Full Text] [Related]
20. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma.
Cheson BD
Radiol Clin North Am; 2008 Mar; 46(2):213-23, vii. PubMed ID: 18619377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]